Charcoal, Activated

Activated charcoal, a form of processed carbon, is being studied in clinical trials for its potential uses in treating various medical conditions. This article explores recent clinical trials investigating the use of activated charcoal in multiple sclerosis and heart failure. We’ll examine how this versatile substance is being evaluated for its ability to enhance drug elimination and potentially improve patient outcomes in these complex diseases.

Table of Contents

What is Activated Charcoal?

Activated charcoal, also known as medicinal carbon or activated carbon, is a form of carbon that has been processed to increase its surface area and porosity[1]. This enhancement gives activated charcoal unique properties that make it useful in various medical applications. It is often used in emergency medicine and as a supportive treatment in certain conditions.

Medical Uses

Activated charcoal has several important medical uses:

  • Poison Treatment: One of the primary uses of activated charcoal is in the treatment of certain types of poisoning. It works by adsorbing (binding to) toxins in the gastrointestinal tract, preventing their absorption into the bloodstream[1].
  • Drug Overdose Management: In cases of drug overdose, activated charcoal can be used to help remove excess medication from the body[2].
  • Accelerated Elimination: Activated charcoal is used in procedures to speed up the elimination of certain substances from the body. This is particularly useful in clinical trials and medical treatments where rapid removal of a drug is necessary[2].
  • Digestive Health: Some people use activated charcoal to alleviate gas and bloating, although scientific evidence for this use is limited.

Administration

Activated charcoal is typically administered orally. It comes in various forms, including:

  • Granules for Oral Suspension: This form is commonly used in clinical settings. For example, one product mentioned in the clinical trials is “Norit Carbomix 50 g granulado para suspensão oral” (granules for oral suspension)[3].
  • Tablets or Capsules: These forms are more commonly found in over-the-counter products.

The dosage of activated charcoal can vary depending on the specific medical situation. In the clinical trials mentioned, the maximum daily dose was reported as 100 grams, with a maximum total dose of 1100 grams over an 11-day period[2]. However, it’s crucial to note that activated charcoal should only be administered under medical supervision, especially in cases of poisoning or drug overdose.

Safety and Side Effects

While activated charcoal is generally considered safe when used appropriately, it can have some side effects and interactions:

  • Constipation: Activated charcoal can cause constipation in some individuals.
  • Black Stools: It typically causes black discoloration of the stools, which is harmless but can be alarming if unexpected.
  • Drug Interactions: Activated charcoal can interfere with the absorption of other medications. It’s important to consult with a healthcare provider about potential interactions[1].

Ongoing Research

While activated charcoal has established uses in emergency medicine and toxicology, researchers continue to explore its potential applications. In the clinical trials reviewed, activated charcoal was mentioned as part of a study investigating treatments for heart failure[3]. However, it’s important to note that in this context, activated charcoal was not the primary focus of the study but was mentioned as a potential tool for accelerated elimination of other drugs.

As with any medical treatment, it’s crucial to use activated charcoal only under the guidance of a healthcare professional. While it has important medical uses, it should not be used indiscriminately or without proper medical supervision.

Aspect Multiple Sclerosis Trials Heart Failure Trial
Primary Use of Activated Charcoal Accelerated elimination procedure Potential adjunct to standard care
Trial Phase Phase 3 Phase 4
Main Objective To demonstrate superiority of remibrutinib over teriflunomide in reducing relapse frequency To assess effectiveness of Digoxin in functional capacity and cardiac function
Key Endpoints Annualized relapse rate, disability progression, MRI lesions Peak oxygen consumption, Global Work Index
Patient Age Range 18 to 55 years 18 years and older
Duration Not specified 48 weeks (24 weeks per treatment arm)

Ongoing Clinical Trials on Charcoal, Activated

  • Study on Reduction of Toxicant Levels in Blood through Combined Digestive Decontamination with Activated Charcoal and Intestinal Purge for Intubated Patients with Major Poisoning in Intensive Care

    Not yet recruiting

    2 1 1 1
    France
  • Study on the Effects of Apixaban Absorption in Patients Undergoing Roux-en-Y Gastric Bypass Surgery

    Not yet recruiting

    3 1 1 1
    The Netherlands
  • Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1
    Investigated diseases:
    Bulgaria Croatia Czechia Estonia France Germany +9
  • Study on the Effects of Digoxin and Activated Charcoal in Treating Heart Failure in Patients Receiving Standard Care

    Not recruiting

    3 1 1 1
    Portugal
  • Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1
    Austria Belgium Bulgaria Croatia Denmark Ireland +7

Glossary

  • Relapsing Multiple Sclerosis (RMS): A form of multiple sclerosis characterized by clearly defined attacks of new or increasing neurologic symptoms, followed by periods of partial or complete recovery.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time.
  • Gadolinium (Gd)-enhancing lesion: An area of active inflammation in the brain or spinal cord that can be seen on an MRI scan after the injection of a contrast agent called gadolinium.
  • Annualized Relapse Rate (ARR): The average number of relapses a patient with multiple sclerosis experiences per year.
  • Neurofilament Light Chain (NfL): A protein released into the bloodstream when nerve cells are damaged, used as a biomarker in multiple sclerosis and other neurological conditions.
  • Left Ventricular Ejection Fraction (LVEF): A measurement of how much blood the left ventricle pumps out with each contraction, used to assess heart function in heart failure.
  • New York Heart Association (NYHA) class: A classification system for heart failure that categorizes patients based on their limitations during physical activity.
  • NTproBNP: A hormone produced by the heart that is elevated in heart failure, used as a biomarker to diagnose and monitor the condition.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-remibrutinib-compared-to-teriflunomide-for-patients-with-relapsing-multiple-sclerosis/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-remibrutinib-compared-to-teriflunomide-for-patients-with-relapsing-multiple-sclerosis-2/
  3. http://clinicaltrials.eu/trial/study-on-the-effects-of-digoxin-and-activated-charcoal-in-treating-heart-failure-in-patients-receiving-standard-care/